{"data":{"issuanceinfo":{"industrycode":"204005","industry":"醫療保健","ipoprice":{"ceiling":"18.080","floor":"15.800"},"ipodate":{"start":"2020-11-09 00:00:00","end":"2020-11-12 00:00:00"},"minimumcapital":"9131.09","subscribed":"264.76","marketcap":"120.81億","H_marketcap":"--","pe":"--","codesrate":"20.00","link":"https://staticpdf.iqdii.com/stockdata/notice/06996/2020/2020110900008_c.pdf","ipopricing":"18.080","resultdate":"2020-11-19 00:00:00","enddate":"2020-11-12 00:00:00","listeddate":"2020-11-20 00:00:00","issuenumber":"15415.35萬","issuenumberhK":"7707.70萬","issuenumberother":"7707.65萬","grayprice":"19.30","sponsors":"高盛(亞洲)有限責任公司,摩根大通證券(遠東)有限公司","raisemoney":"263590.00萬","use":"1、約1,071.1百萬港元（占所得款項凈額的41%）將分配予核心產品；\n2、約654.4百萬港元（占所得款項凈額的25%）將用于為我們的其他四種臨床階段候選藥物提供資金；\n3、約248.9百萬港元（占所得款項凈額的9%）預計將用于本公司管線中的其他臨床前候選藥物正在進行的臨床前研究及計劃進行的臨床試驗；\n4、約359.7百萬港元（占所得款項凈額的14%）預計將用于擴大本公司的研發管線，包括發現新的候選藥物及業務開發活動；\n5、約38.2百萬港元（占所得款項凈額的1%）預計將用于資本開支；\n6、約263.6百萬港元（占所得款項凈額的10%）預計將用于一般公司用途。","shares":500,"leadagent":"高盛(亞洲)有限責任公司,摩根大通證券(亞太)有限公司,花旗環球金融亞洲有限公司,中國國際金融香港證券有限公司,招銀國際融資有限公司,富途證券國際(香港)有限公司","bookrunners":"高盛(亞洲)有限責任公司,摩根大通證券(亞太)有限公司,花旗環球金融亞洲有限公司,中國國際金融香港證券有限公司,招銀國際融資有限公司","coordinator":"高盛(亞洲)有限責任公司,摩根大通證券(亞太)有限公司,花旗環球金融亞洲有限公司,中國國際金融香港證券有限公司","firstDayOpen":"19.60","IsEiio":0,"Interestdays":7,"PENote":"按經審核的最近年度公司股東應占溢利和發行后總股本計算；發行價未確定時，按招股價中間價計算；發行價確定后，按招股定價計算。","OverAllotment":"有","StabilizingManager":"高盛(亞洲)有限責任公司","code":"E06996","name":"德琪醫藥－Ｂ","fullname":"德琪醫藥有限公司"},"institutioninfo":{"principaloffice":"中國上海市長寧區中山西路1065號SOHO中山廣場B座1206-1209室","registrars":"香港中央證券登記有限公司","registrarstel":"(852) 2862 8628","chairman":"梅建明","secretary":"曹洋,王承鏱","telephone":"","substantialshareholders":"梅建明(26.33%),Active Ambience(9.39%),Begonia(8.53%),啟明實體(6.01%)","principalactivities":"公司是一家專注于創新抗腫瘤藥物的亞太地區臨床階段生物制藥公司。","website":"http://www.antengene.com"},"managerinfo":[{"managername":"梅建明","post":"董事長、首席執行官兼執行董事","rankno":1},{"managername":"John F.Chin","post":"執行董事","rankno":2},{"managername":"劉翼騰","post":"執行董事","rankno":3}],"investorinfo":[{"institutionname":"Fidelity International","shareholding":"30,008,000.0","percentage":19.47,"ReleaseDate":"2021-05-20 00:00:00","relatedparty":"富達基金(香港)有限公司","subsidiary":["Fidelity International"],"InverstorType":"基金"},{"institutionname":"GIC Private Limited","shareholding":"8,573,500.0","percentage":5.56,"ReleaseDate":"2021-05-20 00:00:00","relatedparty":"","subsidiary":[],"InverstorType":"公司"},{"institutionname":"Hillhouse Funds","shareholding":"6,430,000.0","percentage":4.17,"ReleaseDate":"2021-05-20 00:00:00","relatedparty":"Hillhouse Capital","subsidiary":["Gaoling Fund, L.P.","Hillhouse Funds","Gaoling Yali Fund, L.P.","HHJH Holdings Limited"],"InverstorType":"基金"},{"institutionname":"BlackRock Funds","shareholding":"6,430,000.0","percentage":4.17,"ReleaseDate":"2021-05-20 00:00:00","relatedparty":"BlackRock, Inc.","subsidiary":["BlackRock Funds"],"InverstorType":"基金"}],"TotalShareholdingPercentage":49.87},"result":1,"Version":"4.5.190802.46408","ElapsedMilliseconds":9}